Skip to main content
SpringerLink
Log in
Book cover

Thérapeutique du cancer pp 219–234Cite as

Cancer bronchique non à petites cellules

  • Chapter

  • 755 Accesses

Résumé

Le cancer bronchopulmonaire primitif (CBP) représente la principale cause de mortalité par cancer dans le monde avec 1,2 million de décès estimés chaque année, dont 252 500 pour la seule Union européenne en 2008 (et 288 100 cas diagnostiqués la même année) [1].

This is a preview of subscription content, log in via an institution.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Ferlay J, Parkin DM, Steliarova-Foucher E (2010) Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 46: 765–781

    Article  PubMed  CAS  Google Scholar 

  2. World Health Organization — International Agency for Research on Cancer (2007). Attributable Causes of Cancer in France in the Year 2000. IARC Working Group Reports: 1–7

    Google Scholar 

  3. Guérin S, Hill C (2010) L’épidémiologie des cancers en France en 2010: comparaison avec les États-Unis. Bull Cancer 97: 47–54

    PubMed  Google Scholar 

  4. Li Y, Sheu CC, Ye Y et al. (2010) Genetic variants and risk of lung cancer in never smokers: a genome-wide association study. Lancet Oncol 11: 321–330

    Article  PubMed  CAS  Google Scholar 

  5. Landi MT, Chatterjee N, Caporaso NE et al. (2010) GPC5 rs2352028 variant and risk of lung cancer in never smokers. Lancet Oncol 11: 714–716

    Article  PubMed  Google Scholar 

  6. Devesa S, Bray F, Vizcaino AP et al. (2005) International lung cancer trends by histologic type: male, female differences diminishing and adenocarcinoma rates rising. Int J cancer 117: 294–299

    Article  PubMed  CAS  Google Scholar 

  7. Kang SM, Kang HJ, Shin JH et al. (2007) Identical epidermal growth factor receptor mutations in adenocarcinomatous and squamous cell carcinomatous components of adenosquamous carcinoma of the lung. Cancer 109: 581–587

    Article  PubMed  CAS  Google Scholar 

  8. Tsao MS, Sakurada A, Cutz JC et al. (2005). Erlotinib in lung cancer — molecular and clinical predictors of outcome. N Engl J Med 353: 133–144

    Article  PubMed  CAS  Google Scholar 

  9. Hirsch FR, Varella-Garcia M, Bunn PA Jr et al. (2006). Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 24: 5034–5042

    Article  PubMed  CAS  Google Scholar 

  10. B Besse, S Vignot, J-C Soria (2010) Point sur les cancers du poumon en 2010 Bull Cancer 97: 161–169

    PubMed  CAS  Google Scholar 

  11. Rusch V, Asamura H, Watanabe H et al. (2009) The IASLC Lung Cancer Staging Project. J Thorac Oncol 4: 568–577

    Article  PubMed  Google Scholar 

  12. Detterbeck FC, Boffa DJ, Tanoue LT (2009) The New Lung Cancer Staging System. Chest 136: 260–271

    Article  PubMed  Google Scholar 

  13. Goldstraw P (2009) Staging Manual in Thoracic Oncology. Ed Orange Park, FL: Editorial Rx Press, p.153

    Google Scholar 

  14. Parkin DM, Pisani P, Ferlay J (1999) Global Cancer Statistics Ca Cancer J Clin 49: 33–64

    Article  PubMed  CAS  Google Scholar 

  15. Crinò L, Weder W, van Meerbeeck J et al. ESMO Guidelines Working Group (2010). Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21Suppl 5: v103–v115

    Article  PubMed  Google Scholar 

  16. Standards, Options and Recommendations (SOR) for the perioperative treatment of patients with resectable non-small cell lung cancer (2007) Rev Mal Respir 24: 1049–1064

    Article  Google Scholar 

  17. Thomas P, Dahan M, Riquet M (2008) Pratiques chirurgicales dans le cancer du poumon non à petites cellules du poumon. Rev Mal Respir 25: 1031–1036

    Article  PubMed  CAS  Google Scholar 

  18. Sabiston DC (1997) Textbook of surgery: the biological basis of modern surgical practice, 15th ed. Philadelphia: WB Saunders; p. 1793

    Google Scholar 

  19. Martel-Lafay I, Fourneret P, Ayadi M et al. (2009) Guide de bonne pratique pour la radiothérapie thoracique exclusive ou post-opératoire des carcinomes non à petites cellules. Cancer/Radiothérapie 13: 55–60

    Article  CAS  Google Scholar 

  20. Qiao X, Tullgren O, Lax I et al. (2003) The role of radiotherapy in treatment of stage I non-small-cell lung cancer. Lung cancer 41: 1–11

    Article  PubMed  Google Scholar 

  21. PORT Meta-analysis Trialists Group (1998) Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. Lancet 352: 257–263

    Article  Google Scholar 

  22. Arriagada R, Bergman B, Dunant A et al. (2004). International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 350: 351–360

    Article  PubMed  Google Scholar 

  23. Winton T, Livingstone R, Johnson D et al. (2005) National Cancer Institute of Canada Clinical Trials Group; National Cancer Institute of the United States Intergroup JBR 10 Trial Investigators. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 352: 2589–2597

    Article  PubMed  CAS  Google Scholar 

  24. Douillard JY, Rosell R, De Lena M et al. (2006) Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IBIIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 7: 719–727

    Article  PubMed  CAS  Google Scholar 

  25. Pignon JP, Tribodet H, Scagliotti GV, LACE Collaborative Group (2008) Lung Adjuvant Cisplatin Evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 26: 3552–3559

    Article  PubMed  Google Scholar 

  26. Depierre A, Milleron B, Moro-Sibilot D et al. (2002). Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer. J Clin Oncol 20: 247–253

    Article  PubMed  Google Scholar 

  27. Burdett S, Stewart LA, Rydzewska L (2006) A systematic review and metaanalysis of the literature: chemotherapy and surgery versus surgery alone in non-small cell lung cancer. J Thorac Oncol 1: 611–621

    Article  PubMed  Google Scholar 

  28. Berghmans T, Paesmans M, Meert AP et al. (2005) Survival improvement in resectable non-small cell lung cancer with (neo)adjuvant chemotherapy: results of a meta-analysis of the literature. Lung Cancer 49: 13–23

    Article  PubMed  CAS  Google Scholar 

  29. Pieterman RM, van Putten JW, Meuzelaar JJ et al. (2000) Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med 343: 254–261

    Article  PubMed  CAS  Google Scholar 

  30. Bryant AS, Cerfolio RJ, Klemm KM et al. (2006). Maximum standard uptake value of mediastinal lymph nodes on integrated FDG-PET-CT predicts pathology in patients with non-small cell lung cancer. Ann Thorac Surg 82: 417–422; discussion 422–3

    Article  PubMed  Google Scholar 

  31. Hunt BM, Vallières E, Buduhan G et al. (2009). Sarcoidosis as a benign cause of lymphadenopathy in cancer patients. Am J Surg 197: 629–632

    Article  PubMed  Google Scholar 

  32. Van Meerbeeck JP, Kramer GW, Van Schil PE et al. European Organisation for Research and Treatment of Cancer-Lung Cancer Group (2007) Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst 99: 442–450

    Article  PubMed  Google Scholar 

  33. Albain KS, Swann RS, Rusch VW et al. (2009) Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet 374: 379–386

    Article  PubMed  CAS  Google Scholar 

  34. Kim TY, Yang SH, Lee SH et al. (2002) A phase III randomized trial of combined chemoradiotherapy versus radiotherapy alone in locally advanced non-small-cell lung cancer. Am J Clin Oncol 25: 238–243

    Article  PubMed  Google Scholar 

  35. Huang EH, Liao Z, Cox JD et al. (2007) Comparison of outcomes for patients with unresectable, locally advanced non-small-cell lung cancer treated with induction chemotherapy followed by concurrent chemoradiation vs. concurrent chemoradiation alone. Int J Radiat Oncol Biol Phys 68: 779–785

    Article  PubMed  CAS  Google Scholar 

  36. Rolland E, Le Chevallier T, Aupérin A (2007) Sequential radio-chimiotherapy (RT-CT) versus radiotherapy alone (RT) and concomitant RT-CT versus RT alone in locally advanced non-small-cell lung cancer (NSCLC): two meta-analyses using individual patient data (IPD) from randomised clinical trials (RCTs). J Thorac Oncol 2: S309–S310

    Article  Google Scholar 

  37. Aupérin A, Le Péchoux C, Pignon JP (2006) Concomitant radio-chimiotherapy based on platin compounds in patients with locally advanced nonsmall-cell lung cancer (NSCLC): A meta-analysis of individual data from 1764 patients. Ann Oncol 17: 473–483

    Article  PubMed  Google Scholar 

  38. D’Addario G, Früh M, Reck M et al. (2010). Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21Suppl 5: v116–v119

    Article  PubMed  Google Scholar 

  39. Daniel C, Kriegel I, Di Maria S et al. (2007). Use of a pleural implantable access system for the management of malignant pleural effusion: the Institut Curie experience. Ann Thorac Surg 84: 1367–1370

    Article  PubMed  Google Scholar 

  40. D’Addario G, Pintilie M, Leighl NB et al. (2005) Platinum-based versus nonplatinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. J Clin Oncol 23: 2926–2936

    Article  PubMed  Google Scholar 

  41. Sandler A, Gray R, Perry MC et al. (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355: 2542–2550

    Article  PubMed  CAS  Google Scholar 

  42. Weng E, Tran L, Rege S et al. (2000). Accuracy and clinical impact of mediastinal lymph node staging with FDG-PET imaging in potentially resectable lung cancer. Am J Clin Oncol 23: 47–52

    Article  PubMed  CAS  Google Scholar 

  43. Changlai SP, Tsai SC, Chou MC et al. (2001) Whole body 18F-2-deoxyglucose positron emission tomography to restage non-small cell lung cancer. Oncol Rep 8: 337–339

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service de chirurgie thoracique, Hôpital Hôtel-Dieu, 1, place du Parvis Notre-Dame, 75181, Paris Cedex 04

    O. N. Pagès

  2. CHU Paris-Seine-Saint-Denis, 125, boulevard de Stalingrad, 93009, Bobigny

    T Bouillet

  3. Service d’oncologie médicale, Hôpital Avicenne, 125, route de Stalingrad, 93009, Bobigny Cedex

    J.-F. Morère

Authors
  1. O. N. Pagès
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T Bouillet
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J.-F. Morère
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer-Verlag France

About this chapter

Cite this chapter

Pagès, O.N., Bouillet, T., Morère, JF. (2011). Cancer bronchique non à petites cellules. In: Thérapeutique du cancer. Springer, Paris. https://doi.org/10.1007/978-2-8178-0021-9_15

Download citation

  • DOI: https://doi.org/10.1007/978-2-8178-0021-9_15

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-8178-0020-2

  • Online ISBN: 978-2-8178-0021-9

Publish with us

Policies and ethics

Search

Navigation